25 XP   0   0   10

Monte Rosa Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Monte Rosa Therapeutics Inc together

PenkeI guess you are interested in Monte Rosa Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Monte Rosa Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Monte Rosa Therapeutics Inc

I send you an email if I find something interesting about Monte Rosa Therapeutics Inc.

Quick analysis of Monte Rosa Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of Monte Rosa Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$3.15
Expected worth in 1 year
$0.89
How sure are you?
15.4%

+ What do you gain per year?

Total Gains per Share
$-2.26
Return On Investment
-41.1%

For what price can you sell your share?

Current Price per Share
$5.50
Expected price per share
$3.82 - $8.22
How sure are you?
50%

1. Valuation of Monte Rosa Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$5.50

Intrinsic Value Per Share

$19.89 - $24.67

Total Value Per Share

$23.04 - $27.82

2. Growth of Monte Rosa Therapeutics Inc (5 min.)




Is Monte Rosa Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$179.2m$297.6m-$92.3m-45.0%

How much money is Monte Rosa Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$33.2m-$26.1m-$7.1m-21.4%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Monte Rosa Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#270 / 1011

Most Revenue
#938 / 1011

Most Profit
#815 / 1011

Most Efficient
#381 / 1011

What can you expect buying and holding a share of Monte Rosa Therapeutics Inc? (5 min.)

Welcome investor! Monte Rosa Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Monte Rosa Therapeutics Inc.

What can you expect buying and holding a share of Monte Rosa Therapeutics Inc?

First you should know what it really means to hold a share of Monte Rosa Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Monte Rosa Therapeutics Inc is $5.5. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Monte Rosa Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Monte Rosa Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $3.15. Based on the TTM, the Book Value Change Per Share is $-0.57 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.38 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Monte Rosa Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.58-10.6%-0.65-11.9%-0.54-9.8%-0.51-9.3%-0.51-9.3%
Usd Book Value Change Per Share-0.53-9.6%-0.57-10.3%-0.38-6.9%0.244.4%0.244.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.53-9.6%-0.57-10.3%-0.38-6.9%0.244.4%0.244.4%
Usd Price Per Share5.65-6.27-9.87-10.00-10.00-
Price to Earnings Ratio-2.42--2.41--4.69--5.30--5.30-
Price-to-Total Gains Ratio-10.65--11.11--27.41--9.99--9.99-
Price to Book Ratio1.79-1.58-1.64-1.70-1.70-
Price-to-Total Gains Ratio-10.65--11.11--27.41--9.99--9.99-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share5.5
Number of shares181
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.570.24
Usd Total Gains Per Share-0.570.24
Gains per Quarter (181 shares)-102.3943.84
Gains per Year (181 shares)-409.58175.36
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-410-4200175165
20-819-8300351340
30-1229-12400526515
40-1638-16500701690
50-2048-20600877865
60-2457-2470010521040
70-2867-2880012281215
80-3277-3290014031390
90-3686-3700015781565
100-4096-4110017541740

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.013.00.00.0%0.013.00.00.0%0.013.00.00.0%
Book Value Change Per Share0.04.00.00.0%2.010.00.016.7%2.011.00.015.4%2.011.00.015.4%2.011.00.015.4%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.013.00.0%0.00.013.00.0%0.00.013.00.0%
Total Gains per Share0.04.00.00.0%2.010.00.016.7%2.011.00.015.4%2.011.00.015.4%2.011.00.015.4%

Fundamentals of Monte Rosa Therapeutics Inc

About Monte Rosa Therapeutics Inc

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1"/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Fundamental data was last updated by Penke on 2024-04-11 09:59:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Monte Rosa Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Monte Rosa Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Monte Rosa Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Monte Rosa Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--196.1%+196.1%
TTM--211.9%+211.9%
YOY--277.7%+277.7%
5Y--432.9%+432.9%
10Y--599.3%+599.3%
1.1.2. Return on Assets

Shows how efficient Monte Rosa Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Monte Rosa Therapeutics Inc to the Biotechnology industry mean.
  • -10.9% Return on Assets means that Monte Rosa Therapeutics Inc generated $-0.11 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Monte Rosa Therapeutics Inc:

  • The MRQ is -10.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -11.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-10.9%TTM-11.8%+0.8%
TTM-11.8%YOY-7.4%-4.3%
TTM-11.8%5Y-10.8%-1.0%
5Y-10.8%10Y-10.8%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-10.9%-13.3%+2.4%
TTM-11.8%-12.7%+0.9%
YOY-7.4%-11.8%+4.4%
5Y-10.8%-14.0%+3.2%
10Y-10.8%-15.9%+5.1%
1.1.3. Return on Equity

Shows how efficient Monte Rosa Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Monte Rosa Therapeutics Inc to the Biotechnology industry mean.
  • -18.6% Return on Equity means Monte Rosa Therapeutics Inc generated $-0.19 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Monte Rosa Therapeutics Inc:

  • The MRQ is -18.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -16.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-18.6%TTM-16.5%-2.0%
TTM-16.5%YOY-8.9%-7.7%
TTM-16.5%5Y-9.1%-7.4%
5Y-9.1%10Y-9.1%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-18.6%-16.9%-1.7%
TTM-16.5%-16.0%-0.5%
YOY-8.9%-15.1%+6.2%
5Y-9.1%-19.7%+10.6%
10Y-9.1%-20.5%+11.4%

1.2. Operating Efficiency of Monte Rosa Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Monte Rosa Therapeutics Inc is operating .

  • Measures how much profit Monte Rosa Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Monte Rosa Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Monte Rosa Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--290.9%+290.9%
TTM--224.4%+224.4%
YOY--288.3%+288.3%
5Y--479.5%+479.5%
10Y--625.2%+625.2%
1.2.2. Operating Ratio

Measures how efficient Monte Rosa Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Monte Rosa Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.110-3.110
TTM-3.266-3.266
YOY-3.783-3.783
5Y-5.657-5.657
10Y-7.783-7.783

1.3. Liquidity of Monte Rosa Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Monte Rosa Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 5.07 means the company has $5.07 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Monte Rosa Therapeutics Inc:

  • The MRQ is 5.070. The company is very able to pay all its short-term debts. +2
  • The TTM is 8.947. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.070TTM8.947-3.877
TTM8.947YOY17.524-8.577
TTM8.9475Y16.115-7.168
5Y16.11510Y16.1150.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.0703.905+1.165
TTM8.9474.212+4.735
YOY17.5245.337+12.187
5Y16.1156.062+10.053
10Y16.1156.401+9.714
1.3.2. Quick Ratio

Measures if Monte Rosa Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Monte Rosa Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 7.24 means the company can pay off $7.24 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Monte Rosa Therapeutics Inc:

  • The MRQ is 7.238. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 14.867. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ7.238TTM14.867-7.630
TTM14.867YOY27.970-13.103
TTM14.8675Y21.077-6.210
5Y21.07710Y21.0770.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.2383.572+3.666
TTM14.8674.001+10.866
YOY27.9705.364+22.606
5Y21.0776.009+15.068
10Y21.0776.287+14.790

1.4. Solvency of Monte Rosa Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Monte Rosa Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Monte Rosa Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.41 means that Monte Rosa Therapeutics Inc assets are financed with 41.0% credit (debt) and the remaining percentage (100% - 41.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Monte Rosa Therapeutics Inc:

  • The MRQ is 0.410. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.281. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.410TTM0.281+0.129
TTM0.281YOY0.156+0.125
TTM0.2815Y0.399-0.119
5Y0.39910Y0.3990.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4100.336+0.074
TTM0.2810.334-0.053
YOY0.1560.271-0.115
5Y0.3990.366+0.033
10Y0.3990.389+0.010
1.4.2. Debt to Equity Ratio

Measures if Monte Rosa Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Monte Rosa Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 69.5% means that company has $0.69 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Monte Rosa Therapeutics Inc:

  • The MRQ is 0.695. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.408. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.695TTM0.408+0.286
TTM0.408YOY0.190+0.218
TTM0.4085Y0.194+0.214
5Y0.19410Y0.1940.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6950.382+0.313
TTM0.4080.397+0.011
YOY0.1900.341-0.151
5Y0.1940.432-0.238
10Y0.1940.465-0.271

2. Market Valuation of Monte Rosa Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Monte Rosa Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Monte Rosa Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -2.42 means the investor is paying $-2.42 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Monte Rosa Therapeutics Inc:

  • The EOD is -2.354. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.418. Based on the earnings, the company is expensive. -2
  • The TTM is -2.408. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.354MRQ-2.418+0.064
MRQ-2.418TTM-2.408-0.011
TTM-2.408YOY-4.694+2.286
TTM-2.4085Y-5.298+2.891
5Y-5.29810Y-5.2980.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.354-2.262-0.092
MRQ-2.418-2.599+0.181
TTM-2.408-2.674+0.266
YOY-4.694-4.133-0.561
5Y-5.298-6.258+0.960
10Y-5.298-6.171+0.873
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Monte Rosa Therapeutics Inc:

  • The EOD is 2.801. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 2.877. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is -1.274. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD2.801MRQ2.877-0.076
MRQ2.877TTM-1.274+4.151
TTM-1.274YOY-4.753+3.479
TTM-1.2745Y-5.441+4.167
5Y-5.44110Y-5.4410.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.801-2.913+5.714
MRQ2.877-3.275+6.152
TTM-1.274-3.508+2.234
YOY-4.753-5.620+0.867
5Y-5.441-8.306+2.865
10Y-5.441-8.854+3.413
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Monte Rosa Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.79 means the investor is paying $1.79 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Monte Rosa Therapeutics Inc:

  • The EOD is 1.747. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.794. Based on the equity, the company is underpriced. +1
  • The TTM is 1.577. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.747MRQ1.794-0.048
MRQ1.794TTM1.577+0.218
TTM1.577YOY1.644-0.067
TTM1.5775Y1.696-0.119
5Y1.69610Y1.6960.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.7471.858-0.111
MRQ1.7942.090-0.296
TTM1.5772.091-0.514
YOY1.6442.866-1.222
5Y1.6963.488-1.792
10Y1.6963.836-2.140
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Monte Rosa Therapeutics Inc.

3.1. Institutions holding Monte Rosa Therapeutics Inc

Institutions are holding 98.104% of the shares of Monte Rosa Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31NEA Management Company, LLC15.33732.8966769229800
2023-12-31FMR Inc11.04050.00245537239-467594-7.787
2023-12-31T. Rowe Price Associates, Inc.9.85150.00384940907107036027.654
2023-12-31Baker Bros Advisors LP9.8020.3161491609500
2023-12-31venBio Select Advisor LLC9.04210.3539453500000
2023-12-31BlackRock Inc4.72940.00032371980-1322688-35.7999
2023-12-31Vanguard Group Inc3.16710.00021588417-39960-2.454
2023-12-31Aisling Capital Management LP2.93562.4814147233100
2023-12-31Alphabet Inc2.9190.3835146401500
2023-09-30Citadel Advisors Llc1.65610.0009830610588467.6249
2023-09-30Octagon Capital Advisors LP1.62080.59828128957929953984.8995
2023-12-31Geode Capital Management, LLC1.37110.0004687671401836.206
2023-12-31State Street Corporation1.14330.0002573409-19349-3.2642
2023-12-31Casdin Capital, LLC1.01860.283351088200
2023-12-31Northern Trust Corp0.56810.0003284934-159028-35.8202
2023-12-31Charles Schwab Investment Management Inc0.48960.000424556230691.2656
2023-12-31ExodusPoint Capital Management, LP0.45820.0085229804-389444-62.8898
2023-12-31TD Asset Management Inc0.38510.001119316800
2023-12-31Candriam Luxembourg S.C.A.0.26920.005313500000
2023-12-31Renaissance Technologies Corp0.20980.00091052001370014.9727
Total 78.01447.337739127417-418910-1.1%

3.2. Funds holding Monte Rosa Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31US Small-Cap Growth II Equity Comp5.50220.0628275958176431538.3064
2023-12-31T. Rowe Price New Horizons5.50220.063275958176431538.3064
2023-12-31HBM Healthcare Investments AG Ord2.80540.3982140704000
2024-02-29Fidelity Growth Compy Commingled Pl O2.16560.00881086131-26600-2.3905
2023-12-31T. Rowe Price Health Sciences1.88150.0362943654-19613-2.0361
2024-02-29Fidelity Select Biotechnology1.87380.12193980500
2024-02-29Vanguard Total Stock Mkt Idx Inv1.68330.000384421900
2024-02-29Fidelity Select Pharmaceuticals Port1.58790.468379640000
2024-03-28iShares Russell 2000 ETF1.5120.00827583143660.0483
2024-02-29Fidelity Growth Company Fund1.32720.0071665621-19000-2.7753
2024-02-29Fidelity Advisor Biotechnology I1.26060.225163225800
2024-01-31Fidelity Small Cap Growth1.24580.0577624825-754-0.1205
2023-12-31T. Rowe Price New Horizons Tr-Z0.96350.063148321019398567.0706
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.87470.002743870783551.9414
2024-01-31Fidelity Small Cap Index0.61330.006630759951201.6927
2024-03-28iShares Russell 2000 Value ETF0.56480.0159283260-180-0.0635
2024-02-29BlackRock Health Sciences Term Trust0.53070.086426616800
2024-02-29Fidelity Growth Company K60.5130.0089257270-5700-2.1675
2024-01-31Fidelity Small Cap Growth K60.45370.05642275307540.3325
2024-02-29Fidelity Series Growth Company0.37310.0075187100-6389-3.302
Total 33.23431.704216668273+1658974+10.0%

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Monte Rosa Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.530-0.566+7%-0.379-28%0.242-319%0.242-319%
Book Value Per Share--3.1493.987-21%5.934-47%4.531-31%4.531-31%
Current Ratio--5.0708.947-43%17.524-71%16.115-69%16.115-69%
Debt To Asset Ratio--0.4100.281+46%0.156+163%0.399+3%0.399+3%
Debt To Equity Ratio--0.6950.408+70%0.190+265%0.194+258%0.194+258%
Dividend Per Share----0%-0%-0%-0%
Eps---0.584-0.655+12%-0.541-7%-0.512-12%-0.512-12%
Free Cash Flow Per Share--0.491-0.330+167%-0.525+207%-0.384+178%-0.384+178%
Free Cash Flow To Equity Per Share--0.933-0.208+122%-0.423+145%0.264+253%0.264+253%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--24.670--------
Intrinsic Value_10Y_min--19.891--------
Intrinsic Value_1Y_max---1.011--------
Intrinsic Value_1Y_min---0.995--------
Intrinsic Value_3Y_max---0.384--------
Intrinsic Value_3Y_min---0.420--------
Intrinsic Value_5Y_max--3.444--------
Intrinsic Value_5Y_min--2.968--------
Market Cap275847550.000-17%321641205.550324033842.138-1%494895581.750-35%504291987.350-36%504291987.350-36%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio1.747-3%1.7941.577+14%1.644+9%1.696+6%1.696+6%
Pe Ratio-2.354+3%-2.418-2.4080%-4.694+94%-5.298+119%-5.298+119%
Price Per Share5.500-3%5.6506.270-10%9.868-43%9.996-43%9.996-43%
Price To Free Cash Flow Ratio2.801-3%2.877-1.274+144%-4.753+265%-5.441+289%-5.441+289%
Price To Total Gains Ratio-10.369+3%-10.652-11.109+4%-27.410+157%-9.986-6%-9.986-6%
Quick Ratio--7.23814.867-51%27.970-74%21.077-66%21.077-66%
Return On Assets---0.109-0.118+7%-0.074-32%-0.108-2%-0.108-2%
Return On Equity---0.186-0.165-11%-0.089-52%-0.091-51%-0.091-51%
Total Gains Per Share---0.530-0.566+7%-0.379-28%0.242-319%0.242-319%
Usd Book Value--179250000.000205288500.000-13%297607500.000-40%228902923.077-22%228902923.077-22%
Usd Book Value Change Per Share---0.530-0.566+7%-0.379-28%0.242-319%0.242-319%
Usd Book Value Per Share--3.1493.987-21%5.934-47%4.531-31%4.531-31%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.584-0.655+12%-0.541-7%-0.512-12%-0.512-12%
Usd Free Cash Flow--27945000.000-15710750.000+156%-26344250.000+194%-19005769.231+168%-19005769.231+168%
Usd Free Cash Flow Per Share--0.491-0.330+167%-0.525+207%-0.384+178%-0.384+178%
Usd Free Cash Flow To Equity Per Share--0.933-0.208+122%-0.423+145%0.264+253%0.264+253%
Usd Market Cap275847550.000-17%321641205.550324033842.138-1%494895581.750-35%504291987.350-36%504291987.350-36%
Usd Price Per Share5.500-3%5.6506.270-10%9.868-43%9.996-43%9.996-43%
Usd Profit---33252000.000-33282750.000+0%-26154500.000-21%-25489461.538-23%-25489461.538-23%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---0.530-0.566+7%-0.379-28%0.242-319%0.242-319%
 EOD+4 -4MRQTTM+16 -13YOY+7 -225Y+6 -2310Y+6 -23

4.2. Fundamental Score

Let's check the fundamental score of Monte Rosa Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.354
Price to Book Ratio (EOD)Between0-11.747
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than17.238
Current Ratio (MRQ)Greater than15.070
Debt to Asset Ratio (MRQ)Less than10.410
Debt to Equity Ratio (MRQ)Less than10.695
Return on Equity (MRQ)Greater than0.15-0.186
Return on Assets (MRQ)Greater than0.05-0.109
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Monte Rosa Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5037.101
Ma 20Greater thanMa 506.837
Ma 50Greater thanMa 1006.379
Ma 100Greater thanMa 2005.725
OpenGreater thanClose5.860
Total4/5 (80.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets303,755
Total Liabilities124,505
Total Stockholder Equity179,250
 As reported
Total Liabilities 124,505
Total Stockholder Equity+ 179,250
Total Assets = 303,755

Assets

Total Assets303,755
Total Current Assets236,212
Long-term Assets67,543
Total Current Assets
Cash And Cash Equivalents 128,101
Short-term Investments 104,312
Net Receivables 505
Other Current Assets 3,294
Total Current Assets  (as reported)236,212
Total Current Assets  (calculated)236,212
+/-0
Long-term Assets
Property Plant Equipment 62,611
Long-term Assets Other 352
Long-term Assets  (as reported)67,543
Long-term Assets  (calculated)62,963
+/- 4,580

Liabilities & Shareholders' Equity

Total Current Liabilities46,592
Long-term Liabilities77,913
Total Stockholder Equity179,250
Total Current Liabilities
Short-term Debt 3,162
Accounts payable 11,152
Other Current Liabilities 14,600
Total Current Liabilities  (as reported)46,592
Total Current Liabilities  (calculated)28,914
+/- 17,678
Long-term Liabilities
Capital Lease Obligations 46,039
Long-term Liabilities  (as reported)77,913
Long-term Liabilities  (calculated)46,039
+/- 31,874
Total Stockholder Equity
Common Stock5
Retained Earnings -365,888
Accumulated Other Comprehensive Income -2,724
Other Stockholders Equity 547,857
Total Stockholder Equity (as reported)179,250
Total Stockholder Equity (calculated)179,250
+/-0
Other
Capital Stock5
Cash and Short Term Investments 232,413
Common Stock Shares Outstanding 56,928
Current Deferred Revenue17,678
Liabilities and Stockholders Equity 303,755
Net Debt -82,062
Net Invested Capital 179,250
Net Working Capital 189,620
Property Plant and Equipment Gross 74,855
Short Long Term Debt Total 46,039



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-31
> Total Assets 
0
0
0
49,378
180,603
368,941
384,049
366,329
346,005
365,056
357,603
342,389
309,028
278,616
252,103
303,755
303,755252,103278,616309,028342,389357,603365,056346,005366,329384,049368,941180,60349,378000
   > Total Current Assets 
0
0
0
43,591
171,707
358,289
370,519
348,666
320,366
297,045
295,235
275,886
240,556
208,104
182,911
236,212
236,212182,911208,104240,556275,886295,235297,045320,366348,666370,519358,289171,70743,591000
       Cash And Cash Equivalents 
0
0
0
41,699
168,436
357,060
367,034
346,071
138,305
103,664
112,394
54,912
51,847
47,027
59,055
128,101
128,10159,05547,02751,84754,912112,394103,664138,305346,071367,034357,060168,43641,699000
       Short-term Investments 
0
0
0
0
0
0
0
0
178,858
190,481
159,755
207,914
179,887
156,039
119,422
104,312
104,312119,422156,039179,887207,914159,755190,481178,85800000000
       Net Receivables 
0
0
0
0
79
40
0
0
0
384
17,557
7,656
2,170
1,154
294
505
5052941,1542,1707,65617,55738400040790000
       Other Current Assets 
0
0
0
1,892
3,271
1,229
3,485
2,595
3,203
2,900
5,529
4,444
5,692
3,884
4,140
3,294
3,2944,1403,8845,6924,4445,5292,9003,2032,5953,4851,2293,2711,892000
   > Long-term Assets 
0
0
0
5,787
8,896
10,652
13,530
17,663
25,639
68,011
62,368
66,503
68,472
70,512
69,192
67,543
67,54369,19270,51268,47266,50362,36868,01125,63917,66313,53010,6528,8965,787000
       Property Plant Equipment 
0
0
0
4,623
7,732
8,923
11,801
12,325
20,306
62,307
57,918
61,907
63,800
65,694
64,400
62,611
62,61164,40065,69463,80061,90757,91862,30720,30612,32511,8018,9237,7324,623000
       Other Assets 
0
0
0
0
1,164
1,729
1,729
5,338
5,333
5,704
4,450
4,596
0
4,818
0
0
004,81804,5964,4505,7045,3335,3381,7291,7291,1640000
> Total Liabilities 
0
0
0
98,106
241,219
12,263
14,744
18,814
20,130
63,006
66,511
70,976
65,302
64,962
67,579
124,505
124,50567,57964,96265,30270,97666,51163,00620,13018,81414,74412,263241,21998,106000
   > Total Current Liabilities 
0
0
0
29,275
9,091
10,791
12,743
16,638
12,490
14,773
21,790
25,569
20,515
19,089
22,609
46,592
46,59222,60919,08920,51525,56921,79014,77312,49016,63812,74310,7919,09129,275000
       Short-term Debt 
0
0
0
0
0
0
0
0
1,524
2,662
3,065
3,127
2,890
2,667
2,881
3,162
3,1622,8812,6672,8903,1273,0652,6621,52400000000
       Accounts payable 
0
0
0
7,066
7,326
7,463
3,530
6,558
4,511
4,294
9,753
7,862
7,382
5,308
5,500
11,152
11,1525,5005,3087,3827,8629,7534,2944,5116,5583,5307,4637,3267,066000
       Other Current Liabilities 
0
0
0
22,209
1,765
3,328
9,213
10,080
6,455
7,817
8,972
14,580
10,243
2,456
2,908
14,600
14,6002,9082,45610,24314,5808,9727,8176,45510,0809,2133,3281,76522,209000
   > Long-term Liabilities 
0
0
0
68,831
232,128
1,472
2,001
2,176
7,640
48,233
44,721
45,407
44,787
45,873
44,970
77,913
77,91344,97045,87344,78745,40744,72148,2337,6402,1762,0011,472232,12868,831000
       Other Liabilities 
0
0
0
0
956
1,472
2,001
2,176
2,183
2,138
2,128
1,533
0
1,505
0
0
001,50501,5332,1282,1382,1832,1762,0011,4729560000
> Total Stockholder Equity
0
0
0
-48,728
-60,616
356,678
369,305
347,515
325,875
302,050
291,092
271,413
243,726
213,654
184,524
179,250
179,250184,524213,654243,726271,413291,092302,050325,875347,515369,305356,678-60,616-48,728000
   Common Stock
0
0
0
1
1
4
5
5
5
5
5
5
5
5
5
5
5555555555411000
   Retained Earnings Total Equity000-262,574-230,536-199,754-172,436-145,967-122,035-98,595-78,75800000
   Accumulated Other Comprehensive Income -2,724-1,455-1,640-1,393-1,752-2,602-2,458-2,133-2,021-1,950-1,415-920-1,056000
   Capital Surplus 
0
0
0
0
0
436,847
469,845
471,566
473,970
476,939
493,443
503,696
507,688
0
0
0
000507,688503,696493,443476,939473,970471,566469,845436,84700000
   Treasury Stock0000000000000000
   Other Stockholders Equity 
0
0
0
404
656
67,906
85,796
471,566
473,970
476,939
493,443
503,696
507,688
513,041
518,610
547,857
547,857518,610513,041507,688503,696493,443476,939473,970471,56685,79667,906656404000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-6,222
Gross Profit-6,222-6,222
 
Operating Income (+$)
Gross Profit-6,222
Operating Expense-137,089
Operating Income-143,311-143,311
 
Operating Expense (+$)
Research Development105,050
Selling General Administrative32,039
Selling And Marketing Expenses0
Operating Expense137,089137,089
 
Net Interest Income (+$)
Interest Income8,956
Interest Expense-0
Other Finance Cost-0
Net Interest Income8,956
 
Pretax Income (+$)
Operating Income-143,311
Net Interest Income8,956
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-135,014-151,608
EBIT - interestExpense = -143,311
-135,014
-135,352
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-143,311-135,014
Earnings Before Interest and Taxes (EBITDA)-137,089
 
After tax Income (+$)
Income Before Tax-135,014
Tax Provision-338
Net Income From Continuing Ops-132,882-135,352
Net Income-135,352
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses143,311
Total Other Income/Expenses Net8,297-8,956
 

Technical Analysis of Monte Rosa Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Monte Rosa Therapeutics Inc. The general trend of Monte Rosa Therapeutics Inc is BULLISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Monte Rosa Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (14.3%) Bearish trend (-14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Monte Rosa Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 5.55 < 6.48 < 8.22.

The bearish price targets are: 4.185 > 3.93 > 3.82.

Tweet this
Monte Rosa Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Monte Rosa Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 8/14.
The longshort score for the Moving Averages is 2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Monte Rosa Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Monte Rosa Therapeutics Inc. The current macd is -0.19642343.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Monte Rosa Therapeutics Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Monte Rosa Therapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Monte Rosa Therapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Monte Rosa Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartMonte Rosa Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Monte Rosa Therapeutics Inc. The current adx is 21.10.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Monte Rosa Therapeutics Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Monte Rosa Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Monte Rosa Therapeutics Inc. The current sar is 7.68422408.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Monte Rosa Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Monte Rosa Therapeutics Inc. The current rsi is 37.10. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending down: The RSI is trending down. -1
Monte Rosa Therapeutics Inc Daily Relative Strength Index (RSI) ChartMonte Rosa Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Monte Rosa Therapeutics Inc. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Monte Rosa Therapeutics Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Monte Rosa Therapeutics Inc Daily Stochastic Oscillator ChartMonte Rosa Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Monte Rosa Therapeutics Inc. The current cci is -160.477166.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Monte Rosa Therapeutics Inc Daily Commodity Channel Index (CCI) ChartMonte Rosa Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Monte Rosa Therapeutics Inc. The current cmo is -41.87033321.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Monte Rosa Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartMonte Rosa Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Monte Rosa Therapeutics Inc. The current willr is -99.63369963.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Monte Rosa Therapeutics Inc Daily Williams %R ChartMonte Rosa Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Monte Rosa Therapeutics Inc. The current atr is 0.59941882.

Monte Rosa Therapeutics Inc Daily Average True Range (ATR) ChartMonte Rosa Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Monte Rosa Therapeutics Inc. The current obv is 626,627.

Monte Rosa Therapeutics Inc Daily On-Balance Volume (OBV) ChartMonte Rosa Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Monte Rosa Therapeutics Inc. The current mfi is 52.27.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Monte Rosa Therapeutics Inc Daily Money Flow Index (MFI) ChartMonte Rosa Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Monte Rosa Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-30WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-01STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-04WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-15MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-26STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-29RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-10RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-01CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-13BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-27ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-19WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-20BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-25ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-26RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-03CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-22STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Monte Rosa Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Monte Rosa Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5037.101
Ma 20Greater thanMa 506.837
Ma 50Greater thanMa 1006.379
Ma 100Greater thanMa 2005.725
OpenGreater thanClose5.860
Total4/5 (80.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Monte Rosa Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Monte Rosa Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Monte Rosa Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Monte Rosa Therapeutics Inc

I send you an email if I find something interesting about Monte Rosa Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Monte Rosa Therapeutics Inc.

Receive notifications about Monte Rosa Therapeutics Inc in your mailbox!